Joint Meeting of the DSaRM and the DODAC - Day 2

The committees will discuss proposed changes to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) requirements to minimize burden on patients, pharmacies, and prescribers while maintaining safe use of isotretinoin oral capsules for patients. Meeting Information and Materials: https://www.fda.gov/advisory-committe...